CD8A and non-small cell lung carcinoma: Our finding was also supported by Han and his colleagues’ study which sequenced the (CDR3) of PD-1+CD8+ TCR Vβ in peripheral blood before and after ICIs therapy [51], suggesting that the diversity and clonality of CD8+ T cells in peripheral blood may serve as noninvasive predictors of patient response and survival outcomes in NSCLC.